Michael A Mohutsky
Overview
Explore the profile of Michael A Mohutsky including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
21
Citations
136
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Hu B, Zhou X, Mohutsky M, Desai P
Mol Pharm
. 2020 Aug;
17(9):3600-3608.
PMID: 32794756
Among the FDA-approved small molecule drugs (2005-2016) that are primarily metabolized by cytochrome P450 (CYP), 64% are primarily metabolized by CYP3A4. As the proportion of an individual drug's fraction metabolized...
2.
Tres F, Posada M, Hall S, Mohutsky M, Taylor L
Pharm Res
. 2019 Oct;
36(12):170.
PMID: 31654151
Purpose: Many bioactive molecules show a type of solution phase behavior, termed promiscuous aggregation, whereby at micromolar concentrations, colloidal drug-rich aggregates are formed in aqueous solution. These aggregates are known...
3.
Zhou X, Cassidy K, Hudson L, Mohutsky M, Sawada G, Hao J
Pharmacol Res Perspect
. 2019 Jul;
7(4):e00502.
PMID: 31333846
The enterohepatic circulation (EHC) of drugs is often the result of the direct glucuronidation, excretion of the metabolite into bile, followed by hydrolysis to the aglycone by the gut microbiome...
4.
Matsunaga N, Ufuk A, Morse B, Bedwell D, Bao J, Mohutsky M, et al.
Drug Metab Dispos
. 2018 Dec;
47(3):215-226.
PMID: 30593544
In the present study, the beagle dog was evaluated as a preclinical model to investigate organic anion transporting polypeptide (OATP)-mediated hepatic clearance. In vitro studies were performed with nine OATP...
5.
Zhou X, Hui Y, Hudson L, Katyayan K, Mohutsky M, Hao J, et al.
J Pharm Sci
. 2018 Sep;
108(2):1017-1026.
PMID: 30244007
1-Aminobenzotriazole (ABT) has been widely used as a nonspecific mechanism-based inhibitor of cytochrome P450 (P450) enzymes. It is extensively used in preclinical studies to determine the relative contribution of oxidative...
6.
Tres F, Posada M, Hall S, Mohutsky M, Taylor L
Int J Pharm
. 2018 Mar;
543(1-2):29-37.
PMID: 29572154
Amorphous solid dispersions (ASDs) are a promising formulation strategy to increase both the apparent aqueous solubility and bioavailability of poorly water-soluble drugs. Upon dissolution under nonsink conditions, ASDs can generate...
7.
Tres F, Hall S, Mohutsky M, Taylor L
J Pharm Sci
. 2017 Oct;
107(1):94-102.
PMID: 29031978
Phase transformations of poorly water-soluble drugs, in low concentration, supersaturated aqueous solutions are of considerable interest. Herein, fluorescence lifetime and steady-state fluorescence spectroscopy were employed to investigate the fluorescence properties...
8.
Rougee L, Mohutsky M, Bedwell D, Ruterbories K, Hall S
Drug Metab Dispos
. 2017 Jul;
45(9):1008-1018.
PMID: 28679672
Surrogate assays for drug metabolism and inhibition are traditionally performed in buffer systems at pH 7.4, despite evidence that hepatocyte intracellular pH is 7.0. This pH gradient can result in...
9.
Rougee L, Mohutsky M, Bedwell D, Ruterbories K, Hall S
Drug Metab Dispos
. 2016 Sep;
44(11):1819-1827.
PMID: 27590024
The proton gradient from the intracellular space to plasma creates an unbound drug gradient for weak acids and bases that could modulate apparent drug clearance and drug-drug interactions. Cytochrome P450...
10.
Zhou X, Rougee L, Bedwell D, Cramer J, Mohutsky M, Calvert N, et al.
Drug Metab Dispos
. 2016 May;
44(8):1184-92.
PMID: 27217490
The Zucker diabetic fatty (ZDF) rat, an inbred strain of obese Zucker fatty rat, develops early onset of insulin resistance and displays hyperglycemia and hyperlipidemia. The phenotypic changes resemble human...